TriSalus Life Sciences, Inc.

As of August 18, 2025, TriSalus Life Sciences, Inc. shows a mildly bearish trend overall, with mixed technical indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -1.8% versus 12.22%.

As of February 9, 2023, TriSalus Life Sciences, Inc. is considered a risky investment due to its negative financial ratios and underperformance compared to peers and the S&P 500.

As of June 20, 2025, TriSalus Life Sciences, Inc. shows a mildly bullish trend based on daily moving averages and monthly MACD, despite mixed signals from weekly indicators and Bollinger Bands suggesting caution and potential volatility.

TriSalus Life Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $10 million as of March 2025, with a market cap of $196.38 million. Key metrics include a negative P/E ratio and a return on equity of 105.18%.

As of Jun 18, TriSalus Life Sciences, Inc. has a market capitalization of 196.38 million, with net sales of 32.14 million and a net profit of -27.22 million over the last four quarters. The company's shareholder's funds are -25.89 million, and total assets are 23.97 million.